ArticleFrontiers in endocrinology2026
Case Report: Rapid loss of endogenous insulin secretion and reversible subcutaneous insulin resistance following exogenous insulin exposure in a patient initially diagnosed with type 2 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subcutaneous insulin resistance (SIR) is a rare condition characterized by impaired responsiveness to subcutaneous insulin despite preserved intravenous insulin efficacy. The coexistence of SIR with rapid loss of endogenous insulin secretion following exogenous insulin exposure has rarely been reported. Case presentation: A 47-year-old Chinese man initially classified as having type 2 diabetes (T2D) had preserved endogenous insulin secretion (random C-peptide, 4.59 ng/mL) and negative insulin autoantibody (IAA), glutamic acid decarboxylase antibody, and insulinoma-associated protein 2 antibody at diagnosis. Shortly after initiation of subcutaneous insulin therapy, he developed pruritic, erythematous, and indurated injection-site lesions with progressive hyperglycemia and subsequently presented with diabetic ketoacidosis. C-peptide became undetectable, whereas IAA increased to >175 IU/mL. Intravenous insulin consistently restored glycemic control, while several subcutaneous insulin preparations were initially ineffective, indicating a marked route-dependent difference in insulin responsiveness. Subcutaneous insulin responsiveness later recovered, first with biphasic protamine human insulin 40/60 and subsequently with insulin analogues, despite persistent IAA positivity. At recent follow-up, 14-day continuous glucose monitoring showed a mean glucose of 7.6 mmol/L, time in range of 80%, and time below range of 3%. A heterozygous Conclusion: This case highlights the coexistence of rapid loss of endogenous insulin secretion and severe but reversible SIR following exogenous insulin exposure. Preserved intravenous insulin responsiveness and recovery of subcutaneous insulin efficacy despite persistent IAA positivity underscore the dynamic and route-specific nature of this phenotype. The underlying mechanism remains uncertain, and no causal relationship with the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.